| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_974a6c3a30820a774065c3ecdd60324e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c5b578dc82d0dab7a01e3398186b6f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6a2a3214798249cfb3f39f46fdb8b22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
| filingDate |
2006-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_defd86c4077b95f568efcafd75b0da3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67575d3061148b39539cbb205addac3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff2be609dbf34a771c7a7c8adbb0dce5 |
| publicationDate |
2007-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007011619-A3 |
| titleOfInvention |
Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate |
| abstract |
An oral, highly bioavailable unit dosage form of O-desmethylvenlafaxine succinate (DVS) having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85 % within about 12 to about 14 hours is described. In one embodiment, the superbioavailable DVS composition has a delayed release of about two hours and a total release of greater than about 95 % within about 12 to about 14 hours. Use of the formulation in treating depression and reducing the gastrointestinal side-effects of O-desmethylvenlafaxine (ODV) is also described. |
| priorityDate |
2005-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |